Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma

Authors

  • T. E. MOLLNES,

    Corresponding author
    1. Institute of Immunology and Rheumatology, Rikshospitalet, The National Hospital, Oslo, Norway, and Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland
    Search for more papers by this author
  • T. LEA,

    1. Institute of Immunology and Rheumatology, Rikshospitalet, The National Hospital, Oslo, Norway, and Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland
    Search for more papers by this author
  • M. HARBOE,

    1. Institute of Immunology and Rheumatology, Rikshospitalet, The National Hospital, Oslo, Norway, and Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland
    Search for more papers by this author
  • J. TSCHOPP

    1. Institute of Immunology and Rheumatology, Rikshospitalet, The National Hospital, Oslo, Norway, and Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland
    Search for more papers by this author

Tom Eirik Mollnes, Institute of Immunology and Rheumatology, Fr. Qvamsgt. I, 0172 Oslo I, Norway

Abstract

The terminal complement complex (TCC), consisting of C5b, C6, C7, C8, and C9, contains neoantigens that are absent from the individual native components. Neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. The present study describes production of monoclonal antibodies against neoantigens of both forms of the TCC. A convenient screening and detection system, based mainly on enzyme-linked immunosorbent assays, crossed immunoelectrophoresis with autoradiography, and affinity chromatography with subsequent sodium dodecyl sulphate-polyacrylamide gel electrophoresis including immunoblotting, is described in detail. Two monoclonal antibodies were specific for a neoantigen located in the poly(C9) moiety of the TCC. One of these antibodies, MCaE11, was used for immunohistochemical detection of MAC in tissue and for quantification of the fluid-phase TCC in ethylenediaminetetraacetic acid plasma.

Ancillary